ZLAB – Zai Lab Limited
Zai Lab LimitedZLAB
$26.43Name : Zai Lab Limited
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $3,271,300,864.00
EPSttm : -1.8
Zai Lab Limited
$26.43
1.60%$0.43
ZLAB — Price & Float Short
—— Fair value
★ EPS beat
★ EPS miss
—— Target Price
Float Short %
Float Short %
8.44
Margin Of Safety %
Put/Call OI Ratio
3.17
EPS Next Q Diff
EPS Last/This Y
-0.31
EPS This/Next Y
-0.14
Price
26.42
Target Price
34.41
Analyst Recom
1.38
Performance Q
3.69
Upside
-188.0%
Beta
0.69
Ticker: ZLAB
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-10-12 | ZLAB | 24.56 | 2.34 | 420.00 | 19107 |
| 2026-10-13 | ZLAB | 23.12 | 2.35 | 13.05 | 19148 |
| 2026-10-14 | ZLAB | 22.49 | 2.36 | 36.11 | 19269 |
| 2026-10-15 | ZLAB | 23.49 | 2.38 | 169.13 | 19428 |
| 2026-10-16 | ZLAB | 23.15 | 2.52 | 17.22 | 20207 |
| 2026-10-19 | ZLAB | 24.06 | 2.60 | 5.90 | 20285 |
| 2026-10-20 | ZLAB | 25.07 | 2.85 | 1.43 | 21941 |
| 2026-10-21 | ZLAB | 24.18 | 2.90 | 5.08 | 22088 |
| 2026-10-22 | ZLAB | 22.04 | 2.96 | 152.73 | 22564 |
| 2026-10-23 | ZLAB | 24.01 | 2.99 | 21.47 | 22732 |
| 2026-10-26 | ZLAB | 24.37 | 2.99 | 6.23 | 23073 |
| 2026-10-27 | ZLAB | 23.56 | 3.02 | 999.99 | 23587 |
| 2026-10-28 | ZLAB | 23.02 | 3.09 | 999.99 | 23995 |
| 2026-10-29 | ZLAB | 22.38 | 3.10 | 3.34 | 24077 |
| 2026-10-30 | ZLAB | 22.11 | 3.09 | 19.83 | 24215 |
| 2026-11-02 | ZLAB | 21.67 | 3.11 | 376.33 | 24397 |
| 2026-11-03 | ZLAB | 21.97 | 3.15 | 66.00 | 24645 |
| 2026-11-04 | ZLAB | 22.83 | 3.17 | 61.17 | 24809 |
| 2026-11-05 | ZLAB | 22.58 | 3.20 | 251.20 | 24983 |
| 2026-11-06 | ZLAB | 25.46 | 3.23 | 1.82 | 25167 |
| 2026-11-09 | ZLAB | 26.86 | 3.24 | 0.19 | 25248 |
| 2026-11-10 | ZLAB | 26.39 | 3.17 | 0.11 | 25438 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-10-12 | ZLAB | 24.59 | -71.0 | - | -2.20 |
| 2026-10-13 | ZLAB | 23.11 | -71.0 | - | -2.20 |
| 2026-10-14 | ZLAB | 22.49 | -71.0 | - | -2.20 |
| 2026-10-15 | ZLAB | 23.50 | -71.0 | - | -2.20 |
| 2026-10-16 | ZLAB | 23.18 | -71.0 | - | -2.20 |
| 2026-10-19 | ZLAB | 24.04 | -71.0 | - | -2.20 |
| 2026-10-20 | ZLAB | 24.04 | -71.0 | - | -2.20 |
| 2026-10-21 | ZLAB | 25.08 | -71.0 | - | -2.20 |
| 2026-10-22 | ZLAB | 22.04 | -71.0 | - | -2.20 |
| 2026-10-23 | ZLAB | 24.03 | -71.0 | - | -2.20 |
| 2026-10-26 | ZLAB | 24.35 | -71.0 | - | -2.20 |
| 2026-10-27 | ZLAB | 23.57 | -71.0 | - | -2.20 |
| 2026-10-28 | ZLAB | 23.01 | -71.0 | - | -2.20 |
| 2026-10-29 | ZLAB | 22.36 | -71.0 | - | -2.20 |
| 2026-10-30 | ZLAB | 22.11 | -71.0 | - | -2.20 |
| 2026-11-02 | ZLAB | 21.67 | -71.0 | - | -2.20 |
| 2026-11-03 | ZLAB | 21.97 | -71.0 | - | -2.20 |
| 2026-11-04 | ZLAB | 22.83 | -79.3 | - | -2.20 |
| 2026-11-05 | ZLAB | 22.59 | -79.3 | - | -2.20 |
| 2026-11-06 | ZLAB | 25.48 | -79.3 | - | -2.20 |
| 2026-11-09 | ZLAB | 26.88 | -79.3 | - | -2.20 |
| 2026-11-10 | ZLAB | 26.42 | -27.6 | - | -1.91 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-10-12 | ZLAB | -3.11 | -5.24 | 6.82 |
| 2026-10-13 | ZLAB | -3.11 | -5.24 | 6.82 |
| 2026-10-14 | ZLAB | -3.11 | -5.24 | 6.82 |
| 2026-10-15 | ZLAB | -3.11 | -5.24 | 6.82 |
| 2026-10-16 | ZLAB | -3.11 | -5.24 | 6.82 |
| 2026-10-19 | ZLAB | -3.11 | -4.51 | 6.82 |
| 2026-10-20 | ZLAB | -3.11 | -4.51 | 6.82 |
| 2026-10-21 | ZLAB | -3.11 | -4.51 | 6.82 |
| 2026-10-22 | ZLAB | -3.11 | -4.51 | 6.82 |
| 2026-10-23 | ZLAB | -3.11 | -4.51 | 6.82 |
| 2026-10-26 | ZLAB | -3.11 | -5.52 | 6.82 |
| 2026-10-27 | ZLAB | -3.11 | -5.52 | 8.44 |
| 2026-10-28 | ZLAB | -3.11 | -5.52 | 8.44 |
| 2026-10-29 | ZLAB | -3.11 | -5.52 | 8.44 |
| 2026-10-30 | ZLAB | -3.11 | -5.52 | 8.44 |
| 2026-11-02 | ZLAB | -3.11 | -3.37 | 8.44 |
| 2026-11-03 | ZLAB | -3.11 | -3.37 | 8.44 |
| 2026-11-05 | ZLAB | -3.11 | -3.37 | 8.44 |
| 2026-11-06 | ZLAB | -3.11 | -3.37 | 8.44 |
| 2026-11-09 | ZLAB | -3.11 | -0.07 | 8.44 |
| 2026-11-10 | ZLAB | -3.11 | -0.07 | 8.44 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
Avg. EPS Est. Current Quarter
-0.59
Avg. EPS Est. Next Quarter
-0.53
Insider Transactions
-3.11
Institutional Transactions
-0.07
Beta
0.69
Average Sales Estimate Current Quarter
102
Average Sales Estimate Next Quarter
116
Fair Value
Quality Score
40
Growth Score
40
Sentiment Score
99
Actual DrawDown %
71.2
Max Drawdown 5-Year %
-84.9
Target Price
34.41
P/E
Forward P/E
PEG
P/S
6.73
P/B
5.28
P/Free Cash Flow
EPS
-1.79
Average EPS Est. Cur. Y
-1.91
EPS Next Y. (Est.)
-2.05
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-44.91
Relative Volume
1.35
Return on Equity vs Sector %
-61.5
Return on Equity vs Industry %
-41.8
EPS 1 7Days Diff
0.3
EPS 1 30Days Diff
0.29
EBIT Estimation
◆
ZLAB
Healthcare
$26.43
Swing / Pullback
Buy the dip on strong trends
WEAK
RSI
60.8
Range 1M
67.3%
Sup Dist
2%
Momentum Growth
Ride accelerating trends
WEAK
EPS Yr
-32.7%
EPS NY
3.5%
52W%
80.9%
Long-Term Value
Quality companies, undervalued
WEAK
🟢 BUY
+30.2% upside
Upside
+30.2%
Quality
40
ZLAB — P/E HistoricalBiotechnology
Zai Lab LimitedSector: Healthcare
Industry: Biotechnology
Employees: 1784
Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases. Its commercial products include Zejula, an orally administered poly (ADP-ribose) polymerase 1/2 inhibitor for treating ovarian cancer; VYVGART, a human IgG1 antibody fragment for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy; NUZYRA for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections; Optune for glioblastoma multiforme; Qinlock for gastrointestinal stromal tumors; Xacduro for treating hospital-acquired and ventilator-associated bacterial pneumonia caused by a cinetobacter baumannii-calcoaceticus complex; and Augtyro for the treatment of ROS proto-oncogene 1 and non-small cell lung cancer. The company has a strategic collaboration with Tesaro, Inc., NovoCure Ltd., Deciphera Pharmaceuticals, LLC, Paratek Bermuda Ltd., argent BV, Turning Point Therapeutics, Inc., Entasis Therapeutics Holdings Inc., Karuna Therapeutics, Inc., Pfizer Inc., Amgen Inc., and with Boehringer Ingelheim GmbH. The company was incorporated in 2013 and is based in Pudong, China.
ZLAB
Latest News
—
Caricamento notizie per ZLAB…
stock quote shares ZLAB – Zai Lab Limited Stock Price stock today
news today ZLAB – Zai Lab Limited stock forecast ,stock prediction 2023 2024 2025
marketwatch ZLAB – Zai Lab Limited yahoo finance google finance
stock history ZLAB – Zai Lab Limited invest stock market
stock prices ZLAB premarket after hours
ticker ZLAB fair value insiders trading